TY - JOUR
T1 - Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression
T2 - An Extensive Review
AU - Sonali, Sharma
AU - Ray, Bipul
AU - Tousif, Hediyal Ahmed
AU - Rathipriya, Annan Gopinath
AU - Sunanda, Tuladhar
AU - Mahalakshmi, Arehally M.
AU - Rungratanawanich, Wiramon
AU - Essa, Musthafa Mohamed
AU - Qoronfleh, M. Walid
AU - Chidambaram, Saravana Babu
AU - Song, Byoung Joon
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Depression is a highly common mental disorder, which is often multifactorial with sex, genetic, environmental, and/or psychological causes. Recent advancements in biomedical research have demonstrated a clear correlation between gut dysbiosis (GD) or gut microbial dysbiosis and the development of anxiety or depressive behaviors. The gut microbiome communicates with the brain through the neural, immune, and metabolic pathways, either directly (via vagal nerves) or indirectly (via gut- and microbial-derived metabolites as well as gut hormones and endocrine peptides, including peptide YY, pancreatic polypeptide, neuropeptide Y, cholecystokinin, corticotropin-releasing factor, glucagon-like peptide, oxytocin, and ghrelin). Maintaining healthy gut microbiota (GM) is now being recognized as important for brain health through the use of probiotics, prebiotics, synbiotics, fecal microbial transplantation (FMT), etc. A few approaches exert antidepressant effects via restoring GM and hypothalamus–pituitary–adrenal (HPA) axis functions. In this review, we have summarized the etiopathogenic link between gut dysbiosis and depression with preclinical and clinical evidence. In addition, we have collated information on the recent therapies and supplements, such as probiotics, prebiotics, short-chain fatty acids, and vitamin B12, omega-3 fatty acids, etc., which target the gut–brain axis (GBA) for the effective management of depressive behavior and anxiety.
AB - Depression is a highly common mental disorder, which is often multifactorial with sex, genetic, environmental, and/or psychological causes. Recent advancements in biomedical research have demonstrated a clear correlation between gut dysbiosis (GD) or gut microbial dysbiosis and the development of anxiety or depressive behaviors. The gut microbiome communicates with the brain through the neural, immune, and metabolic pathways, either directly (via vagal nerves) or indirectly (via gut- and microbial-derived metabolites as well as gut hormones and endocrine peptides, including peptide YY, pancreatic polypeptide, neuropeptide Y, cholecystokinin, corticotropin-releasing factor, glucagon-like peptide, oxytocin, and ghrelin). Maintaining healthy gut microbiota (GM) is now being recognized as important for brain health through the use of probiotics, prebiotics, synbiotics, fecal microbial transplantation (FMT), etc. A few approaches exert antidepressant effects via restoring GM and hypothalamus–pituitary–adrenal (HPA) axis functions. In this review, we have summarized the etiopathogenic link between gut dysbiosis and depression with preclinical and clinical evidence. In addition, we have collated information on the recent therapies and supplements, such as probiotics, prebiotics, short-chain fatty acids, and vitamin B12, omega-3 fatty acids, etc., which target the gut–brain axis (GBA) for the effective management of depressive behavior and anxiety.
KW - Depression
KW - Gut dysbiosis
KW - Gut microbiota
KW - Gut–brain axis
KW - Hypothalamus–pituitary–adrenal axis
KW - Major depressive disorder
KW - Serotonin
KW - Short-chain fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85129778398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129778398&partnerID=8YFLogxK
U2 - 10.3390/cells11081362
DO - 10.3390/cells11081362
M3 - Article
C2 - 35456041
AN - SCOPUS:85129778398
SN - 2073-4409
VL - 11
JO - Cells
JF - Cells
IS - 8
M1 - 1362
ER -